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Abstract: The lupus band test (LBT) is a diagnostic procedure that is used to detect deposits of 
immunoglobulins and complement components along the dermoepidermal junction in patients 
with lupus erythematosus (LE). The LBT is positive in about 70%–80% of sun-exposed non-
lesional skin specimens obtained from patients with systemic LE (SLE), and in about 55% of 
SLE cases if sun-protected nonlesional skin is analyzed. In patients with cutaneous LE only, 
the lesional skin usually shows a positive LBT. The LBT helps in differentiating LE from other 
similar skin conditions and may also be helpful in making the diagnosis of SLE in subjects with no 
specific cutaneous lesions. Furthermore, a positive LBT may be applied as a prognostic parameter 
for LE patients. However, the correct interpretation of this test requires detailed knowledge of 
the site of the biopsy, deposit components, morphology and brightness of the immunofluorescent 
band, and other associated serologic findings, as well as the response to treatment. It must be 
emphasized that LBT is a laboratory procedure that should always be interpreted in conjunction 
with clinical findings and other serological and immunopathological parameters.
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Introduction
Lupus erythematosus (LE) is an autoimmune disease affecting different body systems, 
including, but not limited to, joints, skin, kidneys, blood, heart, and brain, and may be 
characterized by the production of various autoantibodies, complement   consumption, 
and the presence of circulating immune complexes.1 As in other autoimmune   diseases, 
the autoimmune reaction in LE, driven by various components of the immune 
  system, results in inflammation and tissue damage. Systemic LE (SLE), cutaneous 
LE (CLE) (including subacute CLE [SCLE] and discoid LE [DLE]), drug-induced 
LE, and neonatal LE are the major subtypes of LE. Of these, SLE is the most serious 
form. It occurs about 10 times more often among women than among men, usually 
in young adults, and Black and Asian people seem to be more commonly affected.2,3 
This is a life-threatening disease, sometimes with a fatal outcome. Fortunately, the 
medical improvement of patients’ care in the past few decades makes treatment 
  failure   increasingly rare. Currently, the 10-year survival rate in developed countries 
is   estimated to be above 90%.4,5
The histology of the diseased skin of LE patients shows some typical characteristics, 
including vacuolar degeneration of the basal layer with thickened subepidermal base-
ment membrane, as well as perivascular and periadnexal lymphocytic infiltrates, which 
may help to establish the diagnosis.1,6 In addition, lesional and nonlesional skin may Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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show deposits of immunoglobulins along the   dermoepidermal 
junction (DEJ), which is a unique feature of LE.6
Definition of lupus band test (LBT)
Deposits of immunoglobulins at the DEJ, together with 
the thickened basement membrane, in lesional skin of LE 
patients were first described by Burnham et al.7 Subsequently, 
  Cormane8 demonstrated similar deposits in clinically normal 
skin of SLE, but not in that of CLE subjects. Detection of 
these deposits of immunoglobulins and complement compo-
nents in the skin of patients with LE, demonstrable as a linear 
band at the basement membrane zone, was then named the 
lupus band test (LBT). All major immunoglobulin classes 
(IgG, IgM, and IgA) and various complement components 
have been identified in these DEJ deposits.6 The test is done 
on the skin biopsy, usually with direct immunofluorescence 
staining, but immunohistochemistry may also be applied. 
Importantly, LBT can be helpful in distinguishing SLE from 
CLE, because in SLE patients the LBT is frequently posi-
tive in both involved and uninvolved skin, whereas in CLE 
patients only the involved skin is positive.
Although the exact mechanism of the immunoglobulin 
deposition at DEJ in LE patients is not clear, it is believed 
that these immunoglobulins are not antibodies against 
basement membrane zone components but rather represent, 
at least partly, circulating immune complexes of DNA and 
antinuclear antibodies trapped within the DEJ. Furthermore, 
DNA released from ultraviolet-injured keratinocytes, 
although diffusing across the basement membrane zone, 
may bind to collagen IV and then serve as an antigen for 
  circulating antinuclear antibodies.6,9
Sensitivity and specificity  
of the LBT
The sensitivity and specificity of the LBT are strictly related 
to the body area tested and the criteria used for assigning the 
test as positive. For instance, in the study by Cardinali et al10 
on the sun-protected nonlesional skin of SLE patients, the 
sensitivity of the LBT varied between 10.5% and 78.9% and 
the specificity between 47.8% and 97.8%, depending on the 
criteria used by the authors. The most frequent immuno-
globulin class deposited is IgM, which is seen in about 90% 
of lesional skin biopsies, whereas the least frequently seen 
class is IgA.6,11 However, a weak decoration with IgM along 
the DEJ is also common in sun-exposed skin of patients who 
do not have LE. It was demonstrated that healthy sun-exposed 
skin may show a weak interrupted linear or granular pattern of 
IgM and C1q deposits at the DEJ in nearly 25% of samples, 
but only 5% of them showed the presence of IgG, IgA, or 
complement component 3 (C3).12,13 Taking these observations 
into account, in line with Crowson and Magro,6 we suggest 
that LBT should be considered positive when deposits of IgM 
in sun-exposed skin form a continuous band over at least 50% 
of the width of the biopsy specimen which is at least moderate 
in intensity. The predictive value of LBT for SLE was greater 
with C4 (100%), properdin (91.3%), and IgA (86.2%) than 
with IgM (59%).6 The specificity and predictive value also 
increase with the number of immunoreactants detected at 
the DEJ.6 In sun-protected skin, an interrupted band of IgM 
of at least moderate intensity is usually sufficient for desig-
nation as a positive LBT.6 The deposition of IgG is usually 
less intense than that of IgM, and false-positive results are 
practically nonexistent.6
Altogether, the LBT in patients with SLE is positive in 
about 70%–80% subjects when sun-exposed nonlesional 
skin is tested, and in about 55% cases when sun-protected 
nonlesional skin is studied. In patients with CLE, the LBT 
of nonlesional skin is usually negative, although the lesional 
skin may frequently show immune deposits at the DEJ.6 
Moreover, a positive LBT may serve as a prognostic indicator 
in patients with an established diagnosis of LE, as it correlates 
with severe extracutaneous disease, mainly lupus nephritis, 
and with anti-dsDNA antibodies.6,11,14,15
Staining patterns of the LBT
The immunoglobulin staining pattern in nonlesional LE 
skin at low magnification is usually described as granular 
or closely spaced vertically oriented fibrils, and sometimes 
also as a thick, homogeneous band (Figure 1). The C3 
deposits are the most common component, and IgM was 
the most frequent immunoglobulin class observed in the 
LBT.16 Remarkably, a sharply defined, thin linear band at the 
DEJ seen in the pemphigoid should not be considered as a 
positive LBT (Figure 2).6 Under high power, the patterns of 
immunoglobulin deposition at the DEJ may be homogenous 
(Figure 3), fibrillar, stippled (Figure 4), shaggy (Figure 5), 
lumpy (Figure 6), linear, or thready.6,11 All these patterns are 
seen in a continuous fashion. A discontinuous or interrupted 
LBT is less specific and can be seen in a number of other 
disorders such as actinic keratosis, polymorphic light erup-
tion, and rosacea and in normal sun-exposed skin (Table 1).11 
Ultrastructurally, these immunoreactants are deposited on or 
below lamina densa of the basement membrane.11
A stippled pattern of the LBT, consisting of multiple 
small round points of fluorescence (Figure 4), is the type most 
commonly seen in clinically normal skin of SLE. In some Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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patients, sparser, more elongated and threadlike stipples can 
be seen. A homogenous or solid band of well demarcated, 
bright fluorescence is seen mostly in chronic atrophic or 
hypertrophic skin lesions. A thready pattern consisting of 
short, closely set, bright threads or fibrils is seen in more 
acute erythematous, edematous lesions. Shaggy, fibrillar, 
lumpy, and granular patterns have also been seen, usually 
in a continuous pattern along the DEJ.11
Sometimes, a false-negative reaction can be observed due 
to high levels of extravascular IgG deposits in the   dermis.11 
Moreover, considerable anatomic regional variations may 
occur in positive lesional LBT with a cephalocaudal   gradient, 
Figure  1  Positive  lupus  band  test  at  low  magnification:  immunoglobulin  class  M 
deposits  at  the  dermoepidermal  junction  in  sun-protected  nonlesional  skin  in  a 
26-year-old woman with systemic lupus erythematosus (original magnification: ×100).
Figure 2 A sharply defined thin linear band at the dermoepidermal junction in 
pemphigoid (immunoglobulin class G deposits, original magnification: ×200).
Figure 3 Partially homogenous, partially granular pattern of the lupus band test 
(immunoglobulin class M deposits, original magnification ×200).
Table  1  Differential  diagnosis  of  lupus  band  test  in  lupus 
erythematosus from other conditions
Clinical condition Comments
Positive lupus band test Granular band or closely spaced, 
vertically oriented fibrils  
at dermoepidermal junction; sometimes  
a thick, homogeneous band.
Healthy sun-exposed skin May demonstrate positive lupus  
band test.
The band is usually less intensive  
and frequently focal or interrupted.
No reactivity is seen in sun-protected 
skin.
Autofluorescence  
of dermal collagen  
and elastin fibers
Might simulate a positive lesional lupus 
band test.
Artifactual nature of this false-positive 
finding becomes apparent at higher 
magnification.
Bullous pemphigoid Sharply defined thin linear band  
at dermoepidermal junction.
Presence of circulating antibodies against 
basement membrane components  
is helpful for a correct diagnosis.
Porphyrias Fluorescence of the dermoepidermal 
junction is less intense than that found 
in dermal blood vessels, which is exactly 
the reverse of what is seen in lupus 
erythematosus.
Complement is rarely found in the band.
Rosacea The band is less intensive and frequently 
focal or interrupted.
Polymorphic light eruption The band is less intensive and frequently 
focal or interrupted.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
30
Reich et al
with lesions on the head more often being positive than those 
on the trunk.11
Other staining methods in LE
Detection of the C5b-9 macromolecular structure, which is 
formed following activation of the classical or alternative 
component pathway, is another useful tool for the diagnosis 
of LE.1 Intense granular deposition of C5b-9 along the DEJ is 
seen in about 80% of lesional skin in patients with SLE.17 
Vascular decoration for C5b-9 was observed in SLE subjects 
with anti-Ro/SSA antibodies, in patients with circulating 
lupus anticoagulant, or when vasculitis is demonstrated in 
the biopsy.1 Regarding nonlesional skin of SLE patients, C5b-9 
immunoreactivity might be observed within keratinocytes, 
especially in subjects with positive anti-ENA antibodies 
(ENA: Ro, La, Sm, U1RNP). In SCLE and DLE, deposition 
of C5b-9 along the DEJ was observed in 66% and 60% of cases, 
respectively.18 However, in SCLE, keratinocytes may show 
granular nuclear or cytoplasmic reactivity for C5b-9, a finding 
that is usually absent in DLE.1,18
Recently, it was also shown that detection of C3d and C4d 
by immunohistochemistry might be used for diagnosis of LE 
as well.18 C4d is a stable component of classical complement 
activation and represents a degradation product of C4b.19 
C3d is also a stable component of complement activation, 
although it can be formed in both classical or alternative 
complement activation.19 As shown by Magro and Dyrsen,19 
all DLE cases showed granular, moderate to marked intensity 
C3d deposits at DEJ, whereas C4d deposits were found in 
only 15% of DLE patients. Interestingly, all SCLE subjects 
were negative for C3d and C4d staining along the DEJ, 
although some of them showed deposition of C3d or C4d in 
blood vessels, a finding that was also noted in DLE. Similarly 
to DLE, all samples of SLE demonstrated prominent granular 
C3d deposition along the DEJ. Remarkably, all SLE patients 
also had C4d deposits at the DEJ.19
Figure 5 Shaggy pattern of complement component 3 deposits in sun-protected 
lesional skin in patients with subacute cutaneous lupus erythematosus.
Figure 6 Granular (lumpy) pattern of complement component 3 deposits in sun-
protected nonlesional skin in patient with systemic lupus erythematosus (original 
magnification: ×400).
Figure 4 Stippled pattern of complement component 3 deposits in sun-protected 
nonlesional skin in patient with systemic lupus erythematosus (original magnific- 
ation: ×400).Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Application of the LBT
The usefulness of the LBT as a diagnostic procedure in LE 
patients is well established. The positive result of this test 
within the uninvolved skin is a strong indicator of LE.11 
The sensitivity of the LBT for diagnosing an active disease 
seems to be even higher than the value of other laboratory 
parameters, including serum C3 and C4 levels, erythrocyte 
sedimentation rate, lymphocyte count, or the presence of 
anti-dsDNA antibodies (the last two parameters are included 
in the diagnostic criteria of SLE).
The diagnostic specificity of LBT for LE differentiation 
from other inflammatory cutaneous conditions that are clini-
cally similar, such as polymorphic light eruption or benign 
lymphocytic infiltrate of Jessner and Kanoff, is also high.11,16 
Furthermore, a positive LBT in fully sun-protected nonle-
sional skin from the buttocks or inner aspect of the upper arm 
consisting of three or more components (IgA, IgG, IgM, or 
complement proteins) seems to have the highest specificity 
for SLE than any other test.11
The LBT may also be helpful in distinguishing SLE 
from CLE. Various studies have shown that SLE subjects 
have immunoglobulin and/or complement deposits at the 
DEJ in both involved and uninvolved skin, whereas CLE 
patients had only positive LBT in lesional skin. Therefore, 
it is essential to biopsy the appropriate skin site for each 
patient in order to avoid false-negative results. Further-
more, the LBT can be helpful in making a diagnosis of 
SLE in patients without cutaneous lesions. A positive LBT 
in clinically normal skin provides early confirmation of 
SLE, even in patients without LE lesions, where neither 
a biopsy nor LBT can be performed on a skin lesion.11 
Importantly, test positivity was uninfluenced by steroid 
and immunosuppressive therapy.20 The test appears to be 
of great interest for use on all patients who fail to meet 
the criteria for the diagnosis of SLE but whose conditions 
suggest such diagnosis.20 In addition, the LBT facilitates 
differentiation of diagnosis of SLE from other antinuclear 
antibody-positive diseases like rheumatoid arthritis, scle-
roderma, dermatomyositis, and mixed connective tissue 
disease.1,11 However, occasional positive LBTs were found 
in lesional skin of dermatomyositis and systemic sclerosis, 
and this finding has been correlated with a more severe 
disease course.18,21
A positive LBT may also be a predictive value for 
the prognosis of LE patients. The deposition of IgG in 
non  lesional sun-protected skin is correlated with anti-dsDNA 
antibodies titer and with higher incidence of renal disease, 
although a negative LBT does not necessarily exclude 
the possibility of renal involvement.11,20,22 A positive LBT 
within sun-protected normal skin also indicates decreased 
long-term survival.11,22 Recently, Zecevic ´ et al, using the 
SLE Disease Activity Index score, confirmed that the dis-
ease was   significantly more active in patients with positive 
LBT on sun-protected nonlesional skin and in those with a 
higher number of deposited immunoreactants. Moreover, 
almost all patients with renal involvement had a positive 
LBT.23 On the other hand, patients with pure IgM deposi-
tion in clinically normal skin have anti-dsDNA antibodies 
restricted to the IgM class and tend to have a less severe 
disease course. In   addition, C1q deposits along the DEJ in 
the skin of SLE patients may reflect the presence of DNA 
at the DEJ, and such patients have a higher index of disease 
activity.1,14,15
Conclusion
The LBT is a useful diagnostic tool for LE patients. How-
ever, the correct interpretation of this test requires detailed 
knowledge of several correlates, such as the site of the biopsy 
(lesional or normal skin, sun-protected versus sun-exposed 
skin), deposit components, morphology and brightness of 
the immunofluorescent band, and other associated serologic 
findings, as well as the response to treatment. A positive 
LBT on sun-protected nonlesional skin represents a sensi-
tive and specific criterion for identifying patients with LE. 
Furthermore, the LBT on sun-protected normal skin may 
be helpful in diagnosing SLE in patients with inconclusive 
clinical and serological profiles and may also be of prognostic 
significance, particularly if all three (IgG, IgM, and IgA) 
immunoglobulins are found at the DEJ. Importantly, the LBT 
is a laboratory procedure that should always be interpreted in 
conjunction with clinical findings and other serological and 
immunopathological parameters in order to make a   correct 
diagnosis.
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